Research Article| Volume 18, ISSUE 1, P47-51, January 1973

Carbamazepine for painful crises in Fabry's disease

      This paper is only available as a PDF. To read, Please Download here.


      A 28-year-old Japanese man with recurrent crises of excruciating pain in the limbs and lack of sweating since childhood was found to have angiokeratomata on the scrotum. Thin layer chromatographic studies of the urinary sediment disclosed an abnormal accumulation of ceramide trihexoside and confirmed the diagnosis of Fabry's disease. The family history revealed evidence of renal disease in the patient's mother. The painful crises were treated successfully with carbamazepine in a daily dosage of 200 mg. The pharmacological actions of carbamazepine in suppressing various epileptic or painful conditions are reviewed.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Arieff A.J.
        • Mier M.
        Anticonvulsant and psychotropic action of Tegretol. A preliminary report.
        Neurology. 1966; 16: 107-110
        • Bird C.A.K.
        • Griffin B.P.
        • Miklaszewska J.M.
        • Galbraith A.W.
        Tegretol (carbamazepine): a controlled trial of a new anti-convulsant.
        Brit. J. Psychiat. 1966; 112: 737-742
        • Blom S.
        Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G 32883).
        Lancet. 1962; i: 839-840
        • Blom S.
        Tic douloureux, treated with new anticonvulsant: experiences with G 32883.
        Arch. Neurol. (Chic.). 1963; 9: 285-290
        • Brady R.O.
        • Gal A.E.
        • Bradley R.M.
        • Martensson E.
        • Warshaw A.L.
        • Laster L.
        Enzymatic defect in Fabry's disease.
        New Engl. J. Med. 1967; 276: 1163-1167
        • Davis E.
        Clinical evaluation of a new anticonvulsant, G 32883.
        Med. J. Austr. 1964; 1: 150-152
        • Donaldson G.W.K.
        • Graham J.G.
        Aplastic anemia following the administration of Tegretol.
        Brit. J. clin. Pract. 1965; 19: 699-702
        • Espir M.L.E.
        • Millac P.
        Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol).
        J. Neurol. Neurosurg. Psychiat. 1970; 33: 528-531
        • Fromm G.H.
        • Killian J.M.
        Effect of some anticonvulsant drugs on the spinal trigeminal nucleus.
        Neurology. 1967; 17: 275-280
        • Graham J.G.
        • Zilkha K.J.
        Treatment of trigeminal neuralgia with carbamazepine: A follow-up study.
        Brit. med. J. 1966; i: 210-211
        • Hernandez-Péon R.
        Central action of G-32883 upon transmission of trigeminal pain impulses.
        Med. Pharmacol. exp. 1965; 12: 73-80
        • Jongmans J.W.M.
        Report on the anti-epileptic action of Tegretol.
        Epilepsia. 1964; 5: 74-82
        • Kato M.
        • Araki S.
        Paroxysmal kinesigenic choreoathetosis. Report of a case relieved by carbamazepine.
        Arch. Neurol. (Chic.). 1969; 20: 508-513
        • Killian J.M.
        • Fromm G.H.
        Carbamazepine in the treatment of neuralgia. Use and side effects.
        Arch. Neurol. (Chic.). 1968; 19: 129-136
        • Kiluk K.I.
        • Knighton R.S.
        • Newman J.D.
        The treatment of trigeminal neuralgia and other facial pain with carbamazepine.
        Mich. Med. 1968; 67: 1066-1069
        • Kocen R.S.
        • Thomas P.K.
        Peripheral nerve involvement in Fabry's disease.
        Arch. Neurol. (Chic.). 1970; 22: 81-88
        • Krupp P.
        Elektrophysiologische Untersuchungen über den Angriffsmechanismus von Antiepileptika im Tierversuch.
        Helv. paediat. Acta. 1969; 24: 270-277
        • Kuroiwa Y.
        • Shibasaki H.
        Painful tonic seizure in multiple sclerosis. Treatment with diphenylhydantoin and carbamazepine.
        Folia psychiat. neurol. Jap. 1968; 22: 107-119
        • Lewis I.
        Experiences with carbamazepine (Tegretol) in the treatment of facial pain: a report of 49 cases.
        Sth. med. J. (Bgham, Ala,). 1969; 62: 400-404
        • Livingston S.
        • Villamater C.
        • Sakata Y.
        • Pauli L.L.
        Use of carbamazepine in epilepsy. Results in 87 patients.
        J. Amer. med. Ass. 1967; 200: 204-208
        • Lockman L.A.
        • Krivit W.
        • Desnick R.J.
        Relief of the painful crises of Fabry's disease by diphenylhydantoin.
        Neurology (Minneap.). 1971; 21: 423
        • Lorgé M.
        Klinische Erfahrungen mit einem neuen Antiepilepticum. Tegretol (G 32883), mit besonderer Wirkung auf die epileptische Wesensveränderung.
        Schweiz. med. Wschr. 1963; 93: 1042-1047
        • Marjerrison G.
        • Jedlicki S.M.
        • Keogh R.P.
        • Hrychuk W.
        • Poulakakis G.M.
        Carbamazepine: behavioral, anticonvulsant and EEG effects in chronically-hospitalized epileptics.
        Dis. nerv. Syst. 1968; 29: 133-136
        • Sigwald J.
        • Bonduelle M.
        • Sallou C.
        • Raverdy P.
        • Piot C.
        • van Steenbrugghe A.
        Un nouvel anti-épileptique Le carbamyldibenzazépine ou 5-carbamoyl-5H-dibenzo (b, f) azépine (G 32883).
        Presse méd. 1964; 72: 2323-2324
        • Spillane J.D.
        The treatment of trigeminal neuralgia: Preliminary experience with Tegretol.
        Practitioner. 1964; 192: 71-77
        • Theobald W.
        • Kunz H.A.
        Zur Pharmakologie des Antiepilepticums 5-Carbamyl-5H-dibenzo (b, f) azepin.
        Arzneimittel-Forsch. 1963; 13: 122-125